Blood Res.  2020 Mar;55(1):65-67. 10.5045/br.2020.55.1.65.

Daratumumab in dialysis-dependent multiple myeloma

• Jeyaraman
• Bhasin A
• Dayal N
• Pathak S
• Naithani R

• KMID: 2472011
• DOI: http://doi.org/10.5045/br.2020.55.1.65

Abstract

No abstract available.

MeSH Terms

Multiple Myeloma*

Reference

1. Sanchez L, Wang Y, Siegel DS, Wang ML. Daratumumab: a first-in-class CD38 monoclonal antibody for the treatment of multiple myeloma. J Hematol Oncol. 2016; 9:51. PMID: 27363983.

2. Dimopoulos MA, Oriol A, Nahi H, et al. Daratumumab, lenalidomide, and dexamethasone for multiple myeloma. N Engl J Med. 2016; 375:1319–1331. PMID: 27705267.

3. Palumbo A, Chanan-Khan A, Weisel K, et al. Daratumumab, bortezomib, and dexamethasone for multiple myeloma. N Engl J Med. 2016; 375:754–766. PMID: 27557302.

4. Yan X, Clemens PL, Puchalski T, et al. Target-mediated drug disposition of daratumumab following intravenous infusion in relapsed or refractory multiple myeloma after prior proteasome inhibitors and immunomodulatory drugs: a population pharmacokinetic analysis. Blood. 2015; 126:4222.

5. Dimopoulos M, Weisel K, van de Donk NWCJ, et al. Pomalidomide plus low-dose dexamethasone in patients with relapsed/refractory multiple myeloma and renal impairment: results from a phase II trial. J Clin Oncol. 2018; 36:2035–2043. PMID: 29394124.

6. Quach H, White D, Spencer A, et al. Pharmacokinetics and safety of carfilzomib in patients with relapsed multiple myeloma and end-stage renal disease (ESRD): an open-label, single-arm, phase I study. Cancer Chemother Pharmacol. 2017; 79:1067–1076. PMID: 28424963.

7. Ma X, Wong SW, Zhou P, et al. Daratumumab binds to mobilized CD34+ cells of myeloma patients in vitro without cytotoxicity or impaired progenitor cell growth. Exp Hematol Oncol. 2018; 7:27. PMID: 30356940.

8. Cejalvo MJ, Legarda M, Abella E, et al. Activity and safety of daratumumab monotheray in patients with relapsed and refractory multiple myeloma requiring dialysis: preliminary results of Spanish, retrospective, multicenter trial. Blood (ASH Annual Meeting Abstracts). 2017; 130(Suppl 1):1866.

9. Rocchi S, Tacchetti P, Pantani L, et al. Safety and efficacy of daratumumab in dialysis-dependent renal failure secondary to multiple myeloma. Haematologica. 2018; 103:e277–e278. PMID: 29622654.

10. Smyth E, Glavey S, Melotti D, et al. Dialysis independence following single-agent daratumumab in refractory myeloma with renal failure. Ir J Med Sci. 2019; 188:1079–1080. PMID: 30569372.